Načítá se...
Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer
BACKGROUND: Goserelin plus aromatase inhibitors (AI) have already been used in male advanced breast cancer, but the cases that fulvestrantin male breast cancer are rare. CASE PRESENTATION: Here we report a case of long-term (3 years) response to Goserelin plus continuing endocrine treatments given f...
Uloženo v:
| Vydáno v: | World J Surg Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4326472/ https://ncbi.nlm.nih.gov/pubmed/25539790 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-7819-12-393 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|